Yalonda Howze - Jan 19, 2023 Form 4 Insider Report for Codiak BioSciences, Inc. (CDAKQ)

Role
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Signature
/s/ Yalonda Howze
Stock symbol
CDAKQ
Transactions as of
Jan 19, 2023
Transactions value $
-$870
Form type
4
Date filed
1/23/2023, 03:33 PM
Previous filing
Sep 20, 2022
Next filing
Jan 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDAKQ Common Stock Options Exercise +4K 4K Jan 19, 2023 Direct F1
transaction CDAKQ Common Stock Sale -$870 -1.51K -37.8% $0.58* 2.49K Jan 20, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Restricted Stock Units Options Exercise $0 -4K -33.33% $0.00 8K Jan 19, 2023 Common Stock 4K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
F3 Each RSU represents a contingent right to receive one share of common stock.
F4 On January 19, 2022, the reporting person was granted 12,000 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary